|
|
Blood, 1 December 2004, Vol. 104, No. 12, pp. 3558-3564.
Prepublished online as a Blood First Edition Paper on July 22, 2004; DOI 10.1182/blood-2004-04-1535.
 Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS
The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region
Susumu Goyama,
Yuko Yamaguchi,
Yoichi Imai,
Masahito Kawazu,
Masahiro Nakagawa,
Takashi Asai,
Keiki Kumano,
Kinuko Mitani,
Seishi Ogawa,
Shigeru Chiba,
Mineo Kurokawa, and
Hisamaru Hirai
From the Departments of Hematology/Oncology and Regeneration Medicine for Hematopoiesis, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Department of Cell Therapy/Transplantation Medicine, University of Tokyo Hospital, University of Tokyo, Tokyo, Japan; and Department of Hematology, Dokkyo University School of Medicine, Tochigi, Japan.
Acute myelogenous leukemia 1 (AML1; runt-related transcription factor 1 [Runx1]) is a member of Runx transcription factors and is essential for definitive hematopoiesis. Although AML1 possesses several subdomains of defined biochemical functions, the physiologic relevance of each subdomain to hematopoietic development has been poorly understood. Recently, the consequence of carboxy-terminal truncation in AML1 was analyzed by the hematopoietic rescue assay of AML1-deficient mouse embryonic stem cells using the gene knock-in approach. Nonetheless, a role for specific internal domains, as well as for mutations found in a human disease, of AML1 remains to be elucidated. In this study, we established an experimental system to efficiently evaluate the hematopoietic potential of AML1 using a coculture system of the murine embryonic para-aortic splanchnopleural (P-Sp) region with a stromal cell line, OP9. In this system, the hematopoietic defect of AML1-deficient P-Sp can be rescued by expressing AML1 with retroviral infection. By analysis of AML1 mutants, we demonstrated that the hematopoietic potential of AML1 was closely related to its transcriptional activity. Furthermore, we showed that other Runx transcription factors, Runx2/AML3 or Runx3/AML2, could rescue the hematopoietic defect of AML1-deficient P-Sp. Thus, this experimental system will become a valuable tool to analyze the physiologic function and domain contribution of Runx proteins in hematopoiesis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Blood and Runx1: got to have it, really need it
- Stephen D. Nimer
Blood 2004 104: 3420-3421.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Hoogenkamp, M. Lichtinger, H. Krysinska, C. Lancrin, D. Clarke, A. Williamson, L. Mazzarella, R. Ingram, H. Jorgensen, A. Fisher, et al.
Early chromatin unfolding by RUNX1: a molecular explanation for differential requirements during specification versus maintenance of the hematopoietic gene expression program
Blood,
July 9, 2009;
114(2):
299 - 309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. K. Cheng, L. Li, S. H. Cheng, K. M. Lau, N. P. H. Chan, R. S. M. Wong, M. M. K. Shing, C. K. Li, and M. H. L. Ng
Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia
Blood,
October 15, 2008;
112(8):
3391 - 3402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-i. Ohno, T. Sato, K. Kohu, K. Takeda, K. Okumura, M. Satake, and S. Habu
Runx proteins are involved in regulation of CD122, Ly49 family and IFN-{gamma} expression during NK cell differentiation
Int. Immunol.,
January 1, 2008;
20(1):
71 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Miething, R. Grundler, C. Mugler, S. Brero, J. Hoepfl, J. Geigl, M. R. Speicher, O. Ottmann, C. Peschel, and J. Duyster
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment
PNAS,
March 13, 2007;
104(11):
4594 - 4599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nakagawa, M. Ichikawa, K. Kumano, S. Goyama, M. Kawazu, T. Asai, S. Ogawa, M. Kurokawa, and S. Chiba
AML1/Runx1 rescues Notch1-null mutation-induced deficiency of para-aortic splanchnopleural hematopoiesis
Blood,
November 15, 2006;
108(10):
3329 - 3334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Liu, L. Carlsson, and T. Grundstrom
Identification of an N-terminal Transactivation Domain of Runx1 That Separates Molecular Function from Global Differentiation Function
J. Biol. Chem.,
September 1, 2006;
281(35):
25659 - 25669.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Fukushima-Nakase, Y. Naoe, I. Taniuchi, H. Hosoi, T. Sugimoto, and T. Okuda
Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development
Blood,
June 1, 2005;
105(11):
4298 - 4307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kawazu, T. Asai, M. Ichikawa, G. Yamamoto, T. Saito, S. Goyama, K. Mitani, K. Miyazono, S. Chiba, S. Ogawa, et al.
Functional Domains of Runx1 Are Differentially Required for CD4 Repression, TCR{beta} Expression, and CD4/8 Double-Negative to CD4/8 Double-Positive Transition in Thymocyte Development
J. Immunol.,
March 15, 2005;
174(6):
3526 - 3533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
